Biotechnology

DAJY

DAJY released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 254.15 M, actual EPS CNY -0.4391

DAJY released FY2025 annual earnings on April 27 After-Market BJT, actual revenue CNY 757.66 M, actual EPS CNY -0.53

DAJY released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 149.44 M, actual EPS CNY -0.07

DAJY FY2026 Q1 Earning Release on April 28 After-Market (BJT)

DAJY FY2025 Annual Earnings Release on April 3, 2026 After-Market (BJT)

DAJY released FY2025 9 Months Earnings on October 30 During-Market (BJT), actual revenue CNY 503.51 M, actual EPS CNY -0.0907

DAJY released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 164.93 M, actual EPS CNY 0.0281

DAJY FY2025 Q3 Earning Release on October 31, 2025 During-Market (BJT)

DAJY released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 169.44 M, actual EPS CNY -0.1589

DAJY released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 338.57 M, actual EPS CNY -0.13

DAJY FY2025 Semi-Annual Earnings Release on August 30, 2025 (BJT)

Da 安 Gene Announces International Patent for DNA Glycosylase Preparation Method

Daan Gene Obtained Respiratory Pathogen Nucleic Acid Test Kit Registration Certificate

Da 安 Gene Reports Net Profit of 52.9243 Million Yuan in Q1 2025

DAJY released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 169.14 M, actual EPS CNY 0.04

DAJY to Release FY2025 Q1 Earnings Report on April 30 After-Market BJT

Daan Gene Reports First Loss, Investor Inquires About Fundamental Changes and Future Goals

DaAn Gene Releases 2024 Annual Report with Revenue of 853 Million Yuan, Down 27.76% Year-on-Year

DAJY released FY2024 Annual Earnings on March 28 After-Market (BJT), Actual Revenue: CNY 853.02 M, Actual EPS: CNY -0.66

DAJY released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue CNY 261.97 M, actual EPS CNY -0.2979

688317

002022

301080

300639

300482

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

LIFERIVER

ACROBIOSYSTEMS

Hybribio Biotech

WONDFO BIOTECH

SSSW

Orient Biotech

maccura

According to the Zhitong Finance APP, DAJY released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 504 million yuan, a year-on-year decrease of 14.81%. The net loss attributable to shareholders of the listed company was 142 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 325 million yuan

Zhitong

DAJY released its performance for the first three quarters, with a net loss attributable to the parent company of 142 million yuan

DAJY announced that the company will hold the third interim meeting of the ninth board of directors on October 29, 2025, to review and approve the proposal to authorize the management to sell part of the stock assets. The authorization period is within 12 months from the date of approval by this board meeting, with the total number of shares to be reduced through centralized bidding transactions not exceeding 1% of the total share capital of the listed company, and the total number of shares to be reduced through block trading not exceeding 2% of the total share capital of the listed company. This transaction is beneficial for optimizing the company's asset structure, improving asset liquidity, and operational efficiency

DAJY: Authorized management to sell up to 3% of the company's total share capital

DAJY's nucleic acid detection kit for the Chikungunya virus has recently been approved for sale in Guangdong, becoming the first product of its kind in the country. The company stated that the maximum production capacity can be increased to 10 million tests per day within a month to meet market demand. This kit is used for the in vitro qualitative detection of viral nucleic acid in serum samples of suspected cases of Chikungunya fever, with a validity period until September 24, 2030

DAJY's Kunjin virus nucleic acid detection kit launched in Guangdong

According to the Zhitong Finance APP, DAJY announced that the company recently obtained a medical device registration certificate issued by the National Medical Products Administration. The name of the medical device is: Chikungunya Virus Nucleic Acid Detection Kit (Fluorescent PCR Method), registration certificate number: Guo Xie Zhu Zheng 20253401955

DAJY: The nucleic acid detection kit for Chikungunya virus (fluorescent PCR method) has obtained the medical device registration certificate

DAJY recently obtained the medical device registration certificate issued by the National Medical Products Administration. The registered product is the Human Immunodeficiency Virus Type 1 (HIV-1) DNA detection kit, with registration certificate number Guo Xie Zhu Zheng 20253401805, valid until September 4, 2030. This product is used for the in vitro qualitative detection of HIV-1 DNA in whole blood samples

DAJY: Human Immunodeficiency Virus Type 1 (HIV-1) DNA test kit has obtained a medical device registration certificate

DAJY announced that its operating revenue in the first half of 2025 is expected to be 339 million yuan, a year-on-year decrease of 15.44%. The net loss attributable to shareholders of the listed company is expected to be 182 million yuan, a year-on-year narrowing of 54.37%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

DAJY: Net loss of 182 million yuan in the first half of 2025, a year-on-year narrowing of 54.37%

601606

36Kr learned that the three major indices of A-shares opened lower collectively, with the Shanghai Composite Index opening down 0.13%, the Shenzhen Component Index down 0.19%, and the ChiNext Index down 0.2%; the aerospace military industry, biotechnology, and semiconductor sectors led the decline, with GreatWall Military dropping over 3%, and DAJY and SMIC falling over 2%; the precious metals, energy, and banking sectors strengthened, with Zhaojin Mining and Jerry Holding rising over 2%, and Industrial Bank rising 0.48%

36Kr

GreatWall Military

SMIC

The three major A-share indices opened lower collectively, with SMIC falling over 2%

300086

300254

301211

002370

The hepatitis concept sector saw a short-term surge, with KHB hitting the limit up, and C&Y Pharmaceutical, BIOCAUSE HEILEN PHARMA, DAJY, Yatai pharm, and Honz all rising

Honz

C&Y Pharmaceutical

BIOCAUSE HEILEN PHARMA

Yatai pharm

The hepatitis concept sector has seen a short-term surge

300642

The monkeypox concept has seen a surge, with KHB hitting the limit up, and DAJY, Yatai pharm, Lanwei Medical, WONDFO BIOTECH, Tellgen, and LIFERIVER also rising

Tellgen

Monkeypox concept stocks surged, KHB hit the limit up

DAJY(002030.SZ)